RELMADA THERAPEUTICS Confirms NASDAQ Listing on Jan 4, 2024
Ticker: RLMD · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, exchange-listing, regulation-fd
TL;DR
**RLMD confirms NASDAQ listing, no new news.**
AI Summary
RELMADA THERAPEUTICS, INC. filed an 8-K on January 4, 2024, to disclose that its common stock, with a $0.001 par value per share, is registered on The NASDAQ Global Select Market under the trading symbol RLMD. This filing primarily serves to update administrative information and confirm its listing status. For investors, this matters because it reaffirms the company's continued compliance with exchange listing requirements, which is a basic but important indicator of stability and market access for their shares.
Why It Matters
This filing confirms RELMADA THERAPEUTICS, INC.'s continued listing on The NASDAQ Global Select Market, ensuring liquidity and visibility for its common stock (RLMD). It's a routine but essential update for market transparency.
Risk Assessment
Risk Level: low — This 8-K is a routine administrative filing with no new material financial or operational information, indicating very low risk.
Analyst Insight
This filing is purely administrative and does not contain new material information that would warrant an immediate investment action. Investors should continue to monitor for substantive news regarding the company's operations or financial performance.
Key Numbers
- $0.001 — Par Value per Share (The stated par value of RELMADA THERAPEUTICS, INC.'s common stock.)
Key Players & Entities
- RELMADA THERAPEUTICS, INC. (company) — the registrant filing the 8-K
- The NASDAQ Global Select Market (company) — the exchange where the company's stock is registered
- RLMD (company) — the trading symbol for RELMADA THERAPEUTICS, INC.
- $0.001 (dollar_amount) — par value per share of common stock
- January 4, 2024 (date) — date of earliest event reported and filing date
FAQ
What is the primary purpose of this 8-K filing by RELMADA THERAPEUTICS, INC.?
The primary purpose of this 8-K filing, dated January 4, 2024, is to report an event under Regulation FD Disclosure and Financial Statements and Exhibits, specifically confirming the registration of its common stock on The NASDAQ Global Select Market under the trading symbol RLMD.
On which stock exchange is RELMADA THERAPEUTICS, INC.'s common stock traded?
RELMADA THERAPEUTICS, INC.'s common stock, with a $0.001 par value per share, is registered and traded on The NASDAQ Global Select Market.
What is the trading symbol for RELMADA THERAPEUTICS, INC.?
The trading symbol for RELMADA THERAPEUTICS, INC.'s common stock is RLMD.
What is the par value of RELMADA THERAPEUTICS, INC.'s common stock?
The par value of RELMADA THERAPEUTICS, INC.'s common stock is $0.001 per share.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 4, 2024.
Filing Stats: 612 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-01-04 08:11:19
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The NASDAQ
Filing Documents
- ea191114-8k_relmada.htm (8-K) — 28KB
- ea191114ex99-1_relmada.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001213900-24-000999.txt ( ) — 226KB
- rlmd-20240104.xsd (EX-101.SCH) — 3KB
- rlmd-20240104_lab.xml (EX-101.LAB) — 33KB
- rlmd-20240104_pre.xml (EX-101.PRE) — 22KB
- ea191114-8k_relmada_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 4, 2024, Relmada Therapeutics, Inc. (the "Company"), issued a press release that provided a corporate update, highlighting the Company's key 2023 accomplishments and outlining its anticipated 2024 clinical development milestones. Pursuant to Regulation FD, the press release is furnished with this Current Report as Exhibit 99.1. The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), regardless of any general incorporation language in such filing.
01 Financial
Item 9.01 Financial (d) Exhibits. Exhibit No. Description 99.1* Press release issued on January 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * This Exhibit attached to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise Exchange Act, except as expressly set forth by specific reference in such filing. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 4, 2024 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 2